Global Myelodysplastic Syndrome Drugs Market Size 2024, Forecast To 2033
6 Mar, 2024
The myelodysplastic syndrome drugs market size has demonstrated rapid growth in recent years, surging from $2.07 billion in 2023 to $2.28 billion in 2024, with a compound annual growth rate (CAGR) of 10.2%. This growth is driven by factors such as the aging population, advancements in diagnostics, increasing cases of myelodysplastic syndrome related to chemotherapy, a rise in cancer survivors, and extensive clinical research and drug development activities. Looking forward, the market is expected to experience robust growth, reaching $3.26 billion by 2028, with a CAGR of 9.3%. The anticipated growth is fueled by the growing geriatric population, advancements in targeted therapies, enhanced understanding of disease mechanisms, increased awareness and early diagnosis initiatives, and the expansion of oncology research. Major trends anticipated in the forecast period include the optimization of erythropoiesis-stimulating agents, the use of combination therapies, a focus on iron chelation therapy, regulatory approvals, and the adoption of patient-centric care models.
Global Myelodysplastic Syndrome Drugs Market Key Driver
The increase in the incidence of myelodysplastic syndrome is expected to propel the growth of the myelodysplastic syndrome drug market over the coming years. Myelodysplastic syndrome (MDS) is a group of disorders characterized by abnormal development and maturation of blood cells in the bone marrow. It is a type of blood cancer that primarily affects the production of healthy blood cells. Myelodysplastic syndrome drugs are used in treating myelodysplastic syndrome and involve medications to inhibit or modulate the immune system to lessen the requirement for red blood cell transfusions. For instance, in October 2022, according to the American Journal of Managed Care, a US-based magazine, The prevalence of myelodysplastic syndrome in the USA is estimated to be between 60,000 and 175,000 cases. Therefore, an increase in incidences of myelodysplastic syndrome is driving the growth of the myelodysplastic syndrome drug market.
Get A Free Sample Of The Global Myelodysplastic Syndrome Drugs Market ReportGlobal Myelodysplastic Syndrome Drugs Market Segments
The myelodysplastic syndrome drugs market covered in this report is segmented –
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
By Geography:The regions covered in the myelodysplastic syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the Myelodysplastic syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Myelodysplastic Syndrome Drugs Industry Players
Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.
Get The Full Global Myelodysplastic Syndrome Drugs Market Report
Myelodysplastic Syndrome Drugs Market Overview
Myelodysplastic syndrome (MDS) is a diverse set of illnesses in which the bone marrow fails to create enough healthy blood cells (red blood cells, white blood cells, and platelets) due to aberrant cell formation and maturation. This condition is caused by uncontrolled cell growth and division that damages tissue. Myelodysplastic syndrome drugs include epoetin alfa, darbepoetin alfa, filgrastim, and other MDS drugs.
Myelodysplastic Syndrome Drugs Global Market Report 2023 provides data on the global myelodysplastic syndrome drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The myelodysplastic syndrome drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.